Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 1801 AL 1815

Geroneuroprotectors: Effective Geroprotectors for the Brain

Schubert D, Currais A, Goldberg J, Finley K, Petrascheck M, Maher P.

Trends Pharmacol Sci. 2018 Dec;39(12):1004-1007. doi: 10.1016/j.tips.2018.09.008. Epub 2018 Nov 13.

Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's β-amyloid self-assembly

Lee BI, Chung YJ, Park CB.

Biomaterials. 2019 Jan;190-191:121-132. doi: 10.1016/j.biomaterials.2018.10.043. Epub 2018 Oct 30.

Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Okuya M, Matsunaga S, Ikuta T, Kishi T, Iwata N.

J Alzheimers Dis. 2018;66(4):1379-1387. doi: 10.3233/JAD-180888.

Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease

Pradeepkiran JA, Reddy AP, Reddy PH.

Drug Discov Today. 2019 Feb;24(2):616-623. doi: 10.1016/j.drudis.2018.11.005. Epub 2018 Nov 16.

Comparison of Cognitive Intervention Strategies for Older Adults With Mild to Moderate Alzheimer's Disease: A Bayesian Meta-analytic Review

Liang JH, Li JY, Jia RX, Wang YQ, Wu RK, Zhang HB, Hang L, Xu Y, Pan CW.

J Am Med Dir Assoc. 2019 Mar;20(3):347-355. doi: 10.1016/j.jamda.2018.09.017. Epub 2018 Nov 17.

Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects

Kozin SA, Barykin EP, Mitkevich VA, Makarov AA.

Biochemistry (Mosc). 2018 Sep;83(9):1057-1067. doi: 10.1134/S0006297918090079.

Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment

Nguyen KH, Comans TA, Green C.

Int Psychogeriatr. 2018 Nov;30(11):1593-1605. doi: 10.1017/S1041610218001291.

Efficacy of Cognitive Rehabilitation in Alzheimer Disease: A 1-Year Follow-Up Study

Germain S, Wojtasik V, Lekeu F, Quittre A, Olivier C, Godichard V, Salmon E.

J Geriatr Psychiatry Neurol. 2019 Jan;32(1):16-23. doi: 10.1177/0891988718813724. Epub 2018 Nov 26.

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease

Camins A, Ettcheto M, Busquets O, Manzine PR, Castro-Torres RD, Beas-Zarate C, Verdaguer E, Sureda FX, Bulló M, Olloquequi J, Auladell C, Folch J.

Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1.

Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines

Bartolini M, Marco-Contelles J.

Chem Rec. 2019 May;19(5):927-937. doi: 10.1002/tcr.201800155. Epub 2018 Nov 29.

Caregivers' resilience in mild and moderate Alzheimer's disease

Rosa RDLD, Simões-Neto JP, Santos RL, Torres B, Baptista MAT, Kimura NRS, Dourado MCN.

Aging Ment Health. 2020 Feb;24(2):250-258. doi: 10.1080/13607863.2018.1533520. Epub 2018 Nov 30.

New approaches for the treatment of Alzheimer's disease

Fish PV, Steadman D, Bayle ED, Whiting P.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):125-133. doi: 10.1016/j.bmcl.2018.11.034. Epub 2018 Nov 19.

Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1

Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Gonçalves PR, Sakai JT, Mendes PFS, Varela ELP, Monteiro MC.

Oxid Med Cell Longev. 2018 Oct 30;2018:8152373. doi: 10.1155/2018/8152373. eCollection 2018.

Will Europe be ready for the treatment of Alzheimer's disease?

The Lancet Neurology.

Lancet Neurol. 2018 Dec;17(12):1025. doi: 10.1016/S1474-4422(18)30409-5. Epub 2018 Nov 13.

Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease

Wang H, Zhang H.

ACS Chem Neurosci. 2019 Feb 20;10(2):852-862. doi: 10.1021/acschemneuro.8b00391. Epub 2018 Dec 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias